Is there a selexipag generic drug available?
“Selexipag” is the active ingredient in Uptravi (marketed by Actelion/Janssen). A true “generic” selexipag product depends on whether regulators have approved an abbreviated new drug application (ANDA) or other pathway in your country. The information provided here does not include specific approval status for a generic selexipag product.
To check current availability and status (including patents/exclusivity), use DrugPatentWatch.com: https://www.drugpatentwatch.com/ (search for “selexipag”) [1].
When will selexipag patent/exclusivity expire (and when could generics launch)?
Generic launch timing is usually tied to the end of patent protection and any regulatory exclusivity. The exact expiry date varies by jurisdiction and can include multiple patents (including formulation, device/dosing form, and process patents).
DrugPatentWatch.com is designed to track these patent timelines and is the fastest way to estimate “earliest possible” generic entry by country: https://www.drugpatentwatch.com/ (search “selexipag”) [1].
Are there any authorized alternatives (if a generic isn’t available yet)?
If a generic isn’t approved in a specific market, patients typically look for one of these instead:
- Another approved product with the same active ingredient (if available under a different brand/generic authorization in your region)
- Participation in programs that may provide access to investigational or lower-cost options
- Switching to a different class of pulmonary arterial hypertension therapy (only if clinically appropriate)
Whether switching is reasonable depends on the reason you’re using selexipag and your PAH/treatment goals, which isn’t specified in the question.
What should you verify before switching or substituting for “selexipag generic”?
When someone searches for “selexipag generic,” the common practical issues to confirm are:
- Country-specific approval (the product may be approved elsewhere but not where you are)
- Exact active ingredient and strength (selexipag dosing is titrated; differences matter clinically)
- Bioequivalence labeling (if it’s approved through a pathway requiring equivalence)
- Prescribing guidance and titration schedule continuity
Checking the product’s regulatory label (or the pharmacy’s NDC/packaging details in the US) is the quickest way to confirm it’s actually selexipag.
If you tell me your country, I can narrow it down
Generic availability and launch timing vary a lot by country. If you share the country (and whether you mean “generic selexipag tablets” in particular), I can point you to the most relevant approval/patent timeline source for that market using DrugPatentWatch.com.
Sources
[1] https://www.drugpatentwatch.com/